Iambic Therapeutics Stock Forecast
NASDAQ: IAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IAM analyst consensus
Consensus (4 analysts)
strong_buy
Avg. price target
$27.25+107.86%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Iambic Therapeutics (2026-11-21), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $27.25, with a high estimate of $35.00 and a low estimate of $22.00. The average target implies upside of 107.9% from the current price of $13.11.
The spread between the highest and lowest targets is 59.1%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IAM.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 25% |
| Buy | 3 | 75% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-11-21.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $22.00 | +67.81% |
| Average target | $27.25 | +107.86% |
| High target | $35.00 | +166.97% |